BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-azn-camizestrant-fda-extended-review-2026@catalyst-calendar.local
DTSTAMP:20260720T200641Z
DTSTART:20260801T130000Z
DTEND:20260801T133000Z
SUMMARY:AstraZeneca camizestrant SERENA-6 FDA延期审评窗口更新
DESCRIPTION:AstraZeneca披露FDA将camizestrant联合CDK4/6抑制剂用于HR阳性、HER2阴性晚期乳腺癌SERENA-6申请的审评延长至2026年8月，以审阅补充数据。此前该申请经历顾问委员会争议，事件对ctDNA指导治疗切换和口服SERD赛道具有较高不确定性。\\nImpact score: 68\\nExpected: FDA将决定是否接受ctDNA监测驱动的早期治疗切换作为适应症基础，可能影响SERD、CDK4/6联合和分子残留病灶监测策略。\\nAffected: AZN(subject\, unknown\, score 78)\; LLY(peer\, mixed\, score 58)\; PFE(peer\, mixed\, score 54)\; NVS(peer\, mixed\, score 54)\; MRK(peer\, mixed\, score 46)\; IBB(etf\, mixed\, score 45)\\nSources: AstraZeneca FDA decision extension: https://www.astrazeneca.com/media-centre/press-releases/2026/us-fda-decision-date-camizestrant-extended.html\\nFDA ODAC briefing document: https://www.fda.gov/media/192156/download\\nFDA ODAC meeting announcement: https://www.fda.gov/advisory-committees/advisory-committee-calendar/april-30-2026-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04302026\\nAstraZeneca ODAC vote update: https://www.astrazeneca.com/media-centre/press-releases/2026/fda-odac-vote-on-camizestrant-breast-cancer.html\\nAstraZeneca ODAC update: https://www.astrazeneca-us.com/media/press-releases/2026/Update-on-FDA-Advisory-Committee-vote-on-camizestrant-in-combination-with-a-CDK-4-6-inhibitor-for-advanced-HR-positive-breast-cancer.html\\nAstraZeneca advisory committee update: https://www.astrazeneca.com/content/az-us/media/press-releases/2026/Update-on-FDA-Advisory-Committee-vote-on-camizestrant-in-combination-with-a-CDK-4-6-inhibitor-for-advanced-HR-positive-breast-cancer.html\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-azn-camizestrant-fda-extended-review-2026
CATEGORIES:fda\,US\,FDA\,PDUFA extension\,SERD\,breast cancer\,ctDNA\,ESR1\,CDK4/6\,camizestrant\,SERENA-6\,ODAC
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: AstraZeneca camizestrant SERENA-6 FDA延期审评窗口更新
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: AstraZeneca camizestrant SERENA-6 FDA延期审评窗口更新
END:VALARM
END:VEVENT
END:VCALENDAR